Biota partner to market
Monday, 30 March, 2009
Japanese biopharma Daiichi Sankyo, which co-owns a long-acting neuraminidase inhibitor for influenza with Australia’s Biota, has applied to manufacture and market the drug in Japan.
The contract depends on the successful completion of Phase III trials in Asia and on obtaining regulatory approval.
The trials have completed patient enrolment with results expected mid-year, Biota said in a statement.
The drug, CS-8958, is a long-acting flu drug which needs less frequent dosing than current neuraminidase inhibitors such as Roche’s oseltamivir (Tamiflu) and Biota’s own zanamivir (Relenza), which is marketed by GSK.
Daiichi Sankyo has rights to the drug in Japan, but Biota said all other key markets are available for licensing by the partners.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
